title: Bleeding complications of targeted oral anticoagulants: what is the risk?
abstract: The vitamin K antagonists (VKAs) are a widely used class of agent to prevent thromboembolism. In recent years, numerous alternatives to VKAs have been developed, the target-specific oral anticoagulants (TSOACs), which are available in clinical practice. Currently available agents target thrombin and factor Xa. The most significant side effect of these agents, as with VKAs, is the development of bleeding complications. In this review, the risks of major bleeding complications with the TSOACs will be discussed. Data from meta-analyses, randomized controlled trials, and observational studies will be used to highlight bleeding complications associated with TSOACs and warfarin. We highlight the most common causes of major bleeding, GI and intracranial hemorrhage.
authors.affiliation: Department of Emergency Medicine, Section of Medical Toxicology, University of Southern California, Los Angeles, CA; and.
authors.forename: Michael
authors.initials: M
authors.lastname: Levine
authors.affiliation: Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA.
authors.forename: Joshua N
authors.initials: JN
authors.lastname: Goldstein
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects; D019774:Blood Coagulation Factor Inhibitors / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D012307:Risk Factors
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D019774:Blood Coagulation Factor Inhibitors